Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -108.85% | 496.49% | -8.47% | -114.77% | 658.51% |
| Total Depreciation and Amortization | 50.75% | -17.16% | -27.47% | 8.78% | -1.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.87% | -13.57% | 0.62% | -5.88% | 47.29% |
| Change in Net Operating Assets | 174.34% | -6,284.51% | -100.90% | 219.62% | -1,378.29% |
| Cash from Operations | 529.65% | -4.72% | -110.37% | 1,079.34% | -261.73% |
| Capital Expenditure | -75.81% | 60.00% | -2,667.86% | 88.43% | -1,173.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,015.35% | 95.95% | -136.05% | -1,495.39% | 110.30% |
| Cash from Investing | -981.97% | 95.82% | -136.85% | -1,551.47% | 109.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 195.76% | -66.55% | 368.55% | -67.02% | 1,379.89% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 183.87% | -66.55% | 368.55% | -64.27% | 1,266.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 225.19% | 84.91% | -222.64% | 1,392.99% | 67.67% |